Business Wire

Delta Air Lines Named as the World’s Best Performing Airline of 2021; All Nippon Airways as the Most On-time Globally

Share

Cirium, the aviation analytics firm, today released its On-Time Performance Review 2021, the global standard for airline and airport operational performance. Cirium awarded Delta Air Lineswith the Platinum Award, recognizing the Atlanta-based carrier as the world’s best performing airline of the year for Operational Excellence.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211228005093/en/

The new annual award is presented to an airline with outstanding performance considering the complexity of the airline’s operation, volume of flights, diversity of its network and other key operational factors. The Platinum Award is based on a proprietary algorithm that considers an array of parameters and provides an output to compare airlines on a one-to-one basis as far as possible to ensure fairness, accuracy, and integrity.

“It was another challenging year for the aviation industry, however 2021 was certainly better than 2020, marking the start of the recovery,” said Jeremy Bowen, CEO, Cirium. “Delta Air Lines stood out this year when you consider the carrier’s size, network, and passenger delay minutes, as well as the number of completed flights. It’s an outstanding effort and achievement during a difficult period. All Nippon Airlines (ANA) is recognized as the most on-time airline in the world. Delta, ANA and the regional winners are congratulated.”

Cirium’s 2021 On-Time Performance Review reflects the second half of the year when flight volumes returned. Airlines globally operated nearly 25 million flights, a 10% increase from 2020, but still down 36% compared to 2019.

The report reviews the top performing airlines and airports globally and in specific categories.

Global Airlines
All Nippon Airways (ANA) is named as the most on-time airline in the Global category with 95% of its flights on time. The carrier was followed closely by Japan Airlines (JAL) with 94.1% — reflecting the high standard set by Japanese aviation when it comes to on-time performance. In third place was Aeroflot (91%), followed by LATAM (88.7%) and Delta Air Lines (87.8%).

North America
Delta Air Lines takes home the award for most on-time North American airline with 87.7% of its flights arriving on time. The carrier topped Alaska Airlines (81.7%) and American Airlines (80.5%).

Europe
Spanish IAG carriers — Vueling (92.1%), Iberia Express (91.8%) and Iberia (90.3%) — took three of the top five spots in the European category. Notably, Vueling has expanded internationally in 2021 with 65% of its third quarter capacity dedicated to international flights.

Asia Pacific
In the Asia Pacific, leading Japanese airlines ANA and JAL rank at the top. Airlines that operate a flight schedule consisting mainly of international flights wherein a state of near hibernation in Asia. Those carriers with a sizeable domestic market have fared better. This year’s Top 10 in Asia-Pacific is dominated by airlines with a significant domestic operation.

Latin America
Copa Airlines, an airline that was close to a complete shutdown at the start of the pandemic, is making a strong recovery and operating its expanding flight schedules at a very high level of on-time performance. The carrier won the Latin America category with 90.3% of its flights on time, followed by Aerolineas Argentinas (89.2%) and Azul (88.9%).

Middle East and Africa
South African Low-Cost Carrier, Safair, outperforms in the Middle East and Africa category as 96.4% of its flights were on time. The airline did not feature in the On-Time Performance Review 2019, however has expanded its international services to Mauritius — a holiday destination for South Africans — with focused operations. Royal Jordanian (89%) and Emirates (86.7%) rounded out the performers in the region.

Low-Cost Carriers
Solaseed Air, also a Japanese domestic operator and ANA affiliate, tops the Low-Cost Carrier category with 97.9% of its flights on time in 2021. The airline flies a network of 14 routes and has very nimble operations.

Top Global Airports
The report also identifies the world’s leading airports in on-time performance and Tokyo’s international airport, Haneda Airport, ranks as the most on-time airport globally. In 2021, 95.6% of the airport’s flights departed on time.

Cirium’s on-time performance reporting for airlines and airports is the longest-standing of such analysis in the industry, going back 13 years. Cirium resumed reporting in June 2021, as flight volumes returned, with regular monthly updates that help gauge the industry’s performance in getting passengers from point A to point B, on time. Cirium’s on-time performance analysis is based on flight data from over 600 sources of real-time flight information. For an airline to be on time, their flights must arrive at the airport gate within 15 minutes of the scheduled arrival time.

Click here to download the complimentary On-Time Performance Review 2021.

Ends

About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cirium media team (Rachel Humphries/June Lee) at media@cirium.com
Juliett Alpha (Mike Arnot) at cirium@juliettalpha.com
The PC Agency (Paul Charles/Michael Johnson/Callum McGoldrick at cirium@pc.agency

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes7.12.2022 10:39:00 CET | Press release

The DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with empagliflozin compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes.1 When empagliflozin was added to other baseline treatments (diet, exercise, metformin and/or insulin) HbA1c was reduced by 0.84% compared with placebo at week 26 (95% CI –1.50 to –0.19; P=0.012).1 The results were presented today at the International Diabetes Federation (IDF) World Diabetes congress 20221, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005405/en/ The DINAMO (DIabetes study of liNAgliptin and eMpagliflozin in children and adOlescents) trial included youth aged 10-17 years with type 2 diabetes and HbA1c ≥6.5% and ≤10.5%. Participants were randomly assigned treatmen

Opening Ceremony Held for NTHU’s Center for Dissection Education and Research7.12.2022 10:00:00 CET | Press release

The opening ceremony for National Tsing Hua University (NTHU) in Taiwan’s Center for Dissection Education and Research, which cost over NT$100 million, was recently held. The ceremony included a memorial service for the cadaver donors. As an expression of gratitude, the first batch of students in the Post-baccalaureate Program in Medicine also offered Chinese bellflowers to the donors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005054/en/ Students of the Post-baccalaureate Program in Medicine at NTHU offering Chinese bellflowers to those who have donated their cadavers to the program. (Photo: National Tsing Hua University) At the ceremony, former NTHU president Hocheng Hong signed the first donation agreement, which indicates that the donor has unconditionally pledged his body for education and research after death, for the purposes of advancing medical science. Current NTHU president W. John Kao thanked Hocheng fo

BIOCORP Obtains 510(k) FDA Clearance for Mallya ®7.12.2022 07:30:00 CET | Press release

Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, announced today that they have received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: "This approval is a major achievement for BIOCORP and all of our employees who have been heavily involved in this regulatory process. This approval marks a historic achievement for BIOCORP as it allows the commercial launch of our Mallya device in the United States and illustrates BIOCORP's ability to meet the highest regulatory requirements. This news has been eagerly awaited by all our industry partners to commercialize Mallya in the world's largest diabetes market and we are delighted that U.S. patients will soon be able to benefit from Mallya's services. This regulatory milestone will have a positive

Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug Administration for DFP-109177.12.2022 07:11:00 CET | Press release

Delta-Fly Pharma, Inc. announces that DFP-10917, a leading pipeline of the company, is granted Orphan Drug Designation (ODD) by US Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML). Be given to ODD, Delta-Fly Pharma, Inc. can be entitled to seven extra years of marketing exclusivity and receive some benefits such as R&D rebate by getting approval. DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed AML. A Phase 3 clinical study has been underway at MD Anderson Cancer Center in Texas and other major sites of Hematologic Cancer Treatment in USA. The company expects to complete the patients’ enrollment plan soon. Delta-Fly Pharma, Inc. focuses not only on cancer itself but on the whole conditions of cancer patients, and aims to deliver medicines that are recommendable for cancer patients and their families. Company profile Company name Delta-Fly Pharma, Inc. [Tokyo:4598] Capital 3352 million Japanese Ye

SLB Announces Pricing of Debt Tender Offer6.12.2022 22:05:00 CET | Press release

SLB (NYSE: SLB) today announced the consideration payable in connection with the previously announced offer (the “Offer”) by Schlumberger Holdings Corporation, an indirect wholly-owned subsidiary of SLB (“SHC”), to purchase for cash up to a certain amount of the notes listed in the table below (the “Notes”), pursuant to the terms and subject to the conditions set forth in the offer to purchase, dated November 21, 2022 (as may be amended or supplemented from time to time, the “Offer to Purchase”). Capitalized terms used but not defined in this press release have the meanings given to them in the Offer to Purchase. Title of Security CUSIP Numbers Acceptance Priority Level(1) Principal Amount Outstanding Principal Amount to be Purchased Early Tender Premium(1) Reference Security Bloomberg Reference Page Reference Yield Fixed Spread (basis points) Total Consideration (1)(2) 3.750% Senior Notes due 2024 806851AJ0 (144A) / U8066LAG9 (Reg S) 1 $750,000,000 $394,869,000 $30 2.500% U.S. Treasur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom